Tiny Health closed a $33 million Series B led by B Capital, bringing total funding to $46 million, alongside a $5 million research program directed at translational microbiome work. The company reports a 2025 randomized controlled trial in which a targeted microbiome intervention lowered the odds of infant eczema by 83%, with a second trial underway. Capital is allocated to interventional research, practitioner education, and an AI model trained on nearly 200,000 shotgun metagenomic profiles.
Key Points
- $33M Series B lifts Tiny Health funding to $46 million
- Randomized trial reported 83% lower infant eczema odds
- AI model trained on nearly 200,000 metagenomic profiles
Longevity Analysis
Microbiome testing has long produced descriptive reports without actionable direction; an interventional randomized trial with a hard clinical endpoint moves the field toward causal claims rather than correlation. Early gut colonization shapes immune calibration and barrier integrity, which is why an infant endpoint like eczema is a useful proxy for how accurately the body distinguishes threat from harmless exposure — a discrimination that degrades with age and underlies much of late-life inflammatory burden. Scale matters here for interpretation: a reference dataset of this size makes it possible to read an individual's microbial signal against meaningful comparators, and to verify whether a given intervention actually shifted anything.
Original published by LT Wire.